Updates on the Role of Imaging in Cardiac Amyloidosis

Purpose of reviewImaging of cardiac amyloidosis has traditionally been hindered by nonspecific findings or diagnosis late in disease. Recent imaging techniques aim to address these gaps.Recent findingsT1 mapping, extracellular volume (ECV) quantification, myocardial strain imaging, positron emission tomography/computed tomography (PET/CT), bone-seeking agents, and cardiac computed tomography angiography (CCTA) are a few of the imaging modalities and techniques used to image cardiac amyloidosis. Many offer the possibility of earlier cardiac amyloidosis detection. PET/CT and bone-seeking agents may allow for quantification of amyloid deposition as well as treatment response monitoring. Additionally, bone-seeking agents help diagnose transthyretin amyloidosis without the need for endomyocardial biopsy.SummaryNew imaging techniques have helped to expand the role of imaging in cardiac amyloidosis by offering the possibility of earlier disease detection, disease burden quantification, and cardiac amyloid subtype differentiation.